Institute Biofunctional Polymer Materials, Max Bergmann Center of Biomaterials, Leibniz-Institut für Polymerforschung Dresden e.V. Hohe Strasse 6, 01069 Dresden, Germany.
Oslo University Hospital and University of Oslo , 0372 Oslo, Norway.
ACS Appl Mater Interfaces. 2017 Nov 22;9(46):40107-40116. doi: 10.1021/acsami.7b14281. Epub 2017 Nov 9.
Contact between biomedical materials and blood often initiates undesirable pro-coagulant and pro-inflammatory processes. On negatively charged materials, blood coagulation is known to be triggered through autoactivation of Factor XII, while activation on cationic surfaces follows a distinct and so far enigmatic mechanism. Because Factor VII activating protease (FSAP) is known to be activated on positively and on negatively charged macromolecules in plasma, we have investigated its interaction with charged biomaterials and its consequences for coagulation. Several activation processes in blood and plasma were characterized after contact with material surfaces with varied charge. FSAP was found to be exclusively activated by the positively charged surfaces polyethylenimine (PEI) and poly-l-lysine (PLL), not by the negatively charged glass or self-assembled monolayer with carboxyl group termination (SAM-COOH), as well as uncharged (Teflon AF) surfaces. Whole blood incubation on PEI showed that this activation was concomitant with coagulation as determined by thrombin and fibrin formation, which was high for glass (F1+2, 138 nM) and PEI (F1+2, 44 nM) but low for Teflon AF (F1+2, 3.3 nM) and SAM COOH (F1+2, 5.8 nM). Contact phase inhibitor diminished coagulation to background levels for all surfaces except PEI (F1+2: ^PEI 43 to 25 nM; glass, 58 to 1.5 nM) indicating that coagulation activation is not dependent on FXII activation on the PEI surface. A decisive role of endogenous FSAP for coagulation however was confirmed with the use of FSAP inhibitory antibodies which showed no influence on Teflon AF, glass and SAM COOH but diminished F1+2 on PEI to less than 50%. We propose that FSAP activation could be a novel mechanism of surface-driven coagulation. An inhibition of this protease might improve hemocompatibility of cationic surfaces and therefore facilitate the application of polycationic surfaces in blood.
生物医学材料与血液接触通常会引发不良的促凝和促炎过程。已知在带负电荷的材料上,血液凝固是通过因子 XII的自动激活触发的,而在带正电荷的表面上,激活则遵循一种独特且迄今仍神秘的机制。由于因子 VII 激活蛋白酶 (FSAP) 已知在血浆中的带正电荷和带负电荷的大分子上被激活,我们研究了它与带电荷的生物材料的相互作用及其对凝血的影响。在与具有不同电荷的材料表面接触后,我们对血液和血浆中的几种激活过程进行了表征。发现 FSAP 仅被带正电荷的表面聚乙烯亚胺 (PEI) 和聚-L-赖氨酸 (PLL) 激活,而不能被带负电荷的玻璃或带竣基端的自组装单分子层 (SAM-COOH) 以及不带电荷的 (特氟龙 AF) 表面激活。全血在 PEI 上孵育表明,这种激活伴随着凝血的发生,这可以通过凝血酶和纤维蛋白形成来确定,对于玻璃 (F1+2,138 nM) 和 PEI (F1+2,44 nM) 较高,但对于特氟龙 AF (F1+2,3.3 nM) 和 SAM COOH (F1+2,5.8 nM) 较低。接触相抑制剂使除 PEI 之外的所有表面的凝血降至背景水平 (F1+2: ^PEI 从 43 降至 25 nM;玻璃,从 58 降至 1.5 nM),表明凝血激活不依赖于 PEI 表面上的 FXII 激活。然而,使用 FSAP 抑制性抗体证实了内源性 FSAP 对凝血的决定性作用,该抗体对特氟龙 AF、玻璃和 SAM COOH 没有影响,但将 PEI 上的 F1+2 降低到小于 50%。我们提出 FSAP 激活可能是一种新的表面驱动凝血机制。抑制这种蛋白酶可能会改善阳离子表面的血液相容性,从而促进阳离子表面在血液中的应用。